2-氯-1-(2,2,4,6-四甲基-2H-喹啉-1-基)-乙酮 | 4593-20-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-氯-1-(2,2,4,6-四甲基-2H-喹啉-1-基)-乙酮
• 中文别名: 1-(氯乙酰基)-4-甲基六氢吡啶；2-氯-1-(4-甲基-1-哌啶基)乙酮；2-氯-1-(4-甲基哌啶-1-基)乙酮
• 英文名称: 1-chloroacetyl-4-methyl-piperidine
• 英文别名: 1-Chloracetyl-4-methyl-piperidin；2-chloro-1-(4-methyl-piperidin-1-yl)-ethanone；2-chloro1-(4-methyl-piperidin-1-yl)-ethanone；N-(α-chloroacetyl)-4-methylpiperidine；2-chloro-1-(4-methylpiperidin-1-yl)ethanone；1-(α-chloroacetyl)-4-pipecoline
• CAS: 4593-20-8
• 化学式: C₈H₁₄ClNO
• mdl: MFCD00297017
• 分子量: 175.658
• InChiKey: NWGYRQNLZDGOQG-UHFFFAOYSA-N

物化性质

• 沸点：
  114 °C(Press: 0.8 Torr)
• 密度：
  1.096±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-氯-1-(2,2,4,6-四甲基-2H-喹啉-1-基)-乙酮 以 乙醇 为溶剂， 生成 1-(α-thiocyanoacetyl)-4-pipecoline
  参考文献：
  名称：

  Compositions of matter D-hetero-1,1-(.alpha.-thiocyanoacetyl) compounds

  摘要：

  该发明揭示了具有以下结构式的新化学物质组合： 其中A是具有3至7个碳原子的饱和或单不饱和脂肪烃链，可选地含有最多三个从烷基、烷氧基和卤素组成的取代基；n是1至3之间的整数。该发明还揭示了一种杀虫杀菌组合物，包括惰性载体和作为必需活性成分的上述描述的化合物，其对昆虫和真菌有毒，以及一种控制昆虫和真菌的方法，包括将上述杀虫杀菌组合物应用于所述昆虫或真菌的生长地点。

  公开号：

  US03998808A1
• 作为产物：
  描述：

  4-甲基哌啶 、 氯乙酰氯 在 碳酸氢钠 作用下， 以 乙腈 为溶剂， 生成 2-氯-1-(2,2,4,6-四甲基-2H-喹啉-1-基)-乙酮
  参考文献：
  名称：

  带有 1,2,3-三唑单元的新型邻苯二甲酰亚胺衍生物的合成、光谱表征以及通过计算机研究作为潜在 SARS-CoV-2 抑制剂的检验

  摘要：

   [显示省略]

  DOI：

  10.1016/j.molstruc.2022.132915

文献信息

• [EN] COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF<br/>[FR] COMPOSES AYANT UNE ACTIVITE AU NIVEAU DU RECEPTEUR 5HT2C ET LEURS UTILISATIONS
  申请人：GLAXO GROUP LTD

  公开号：WO2004081010A1

  公开（公告）日：2004-09-23

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein Q is phenyl or a 6-membered heteroaromatic group containing at least one nitrogen atom; A is -(CH2-CH2)-, -(CH=CH)-, -(CH2)3-, -C(CH3)2-, -(CH=CH-CH2)-, or a group -(CHR3)- wherein R3 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy or C1-6alkylthio; B is O, S or NR11, wherein R11 is hydrogen, C1-6alkyl optionally substituted by C1-6alkoxy, or is C1-6alkanoyl optionally substituted by C1-6alkoxy; R1 is halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy, C1-6alkylthio, hydroxy, amino, mono- or di-C1- 6alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC1-6alkyl, haloC1-6alkoxy, aryl, arylC1-6alkyl, arylC1-6alkyloxy, arylC1-6alkylthio, COR4 (wherein R4 is amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group), COOR5 or COR6 (wherein R5 and R6 are independently hydrogen or C1-6alkyl); p is 0, 1 or 2 or 3; R2 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C1-6alkanoyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylthio, amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is oxygen, sulfur, -CH2- or NR8 wherein R8 is hydrogen or C1-6alkyl; Y is a single bond, -CH2-, -(CH2)2- or -CH=CH-; and Z is an optionally substituted N-linked heterocyclic group or a C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, or Z is -NR9R10 where R9 and R10 are independently hydrogen or C1-6alkyl. Method of preparation and uses thereof in therapy, such as for example in treatment of depression and anxiety, are also disclosed.

  公开了具有式（I）的化合物及其药学上可接受的盐：其中Q是苯或含有至少一个氮原子的6元杂芳基团；A是-(CH2-CH2)-，-(CH=CH)-，-(CH2)3-，-C(CH3)2-，-(CH=CH-CH2)-，或一个-(CHR3)-基团，其中R3是氢，卤素，羟基，氰基，硝基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基或C1-6烷基硫基；B是O，S或NR11，其中R11是氢，C1-6烷基，可选择地被C1-6烷氧基取代，或是C1-6烷酰基，可选择地被C1-6烷氧基取代；R1是卤素，氰基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，C1-6烷氧基，C1-6烷基硫基，羟基，氨基，单或双C1-6烷基氨基，N-连接的4到7成员杂环基团，硝基，卤代C1-6烷基，卤代C1-6烷氧基，芳基，芳基C1-6烷基，芳基C1-6烷氧基，芳基C1-6烷硫基，COR4（其中R4是氨基，单或双C1-6烷基氨基或N-连接的4到7成员杂环基团），COOR5或COR6（其中R5和R6独立地是氢或C1-6烷基）；p是0，1，2或3；R2是氢，卤素，羟基，氰基，硝基，C1-6烷基，C1-6烷酰基，C3-7环烷基，C3-7环烷氧基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基，C1-6烷基硫基，氨基，单或双C1-6烷基氨基或N-连接的4到7成员杂环基团；X是氧，硫，-CH2-或NR8，其中R8是氢或C1-6烷基；Y是单键，-CH2-，-(CH2)2-或-CH=CH-；Z是一个可选择地取代的N-连接杂环基团或含有至少一个氮的C-连接的4到7成员杂环基团，或Z是-NR9R10，其中R9和R10独立地是氢或C1-6烷基。还公开了其制备方法及在治疗中的用途，例如在抑郁症和焦虑症的治疗中。
• [EN] COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE PAR RAPPORT AU RECEPTEUR 5HT2C ET LEURS APPLICATIONS
  申请人：GLAXO GROUP LTD

  公开号：WO2004089897A1

  公开（公告）日：2004-10-21

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein R1 is halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy, C1 6alkylthio, hydroxy, amino, mono or di C1 6alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC1-6alkyl, haloC1-6alkoxy, aryl, -COOR3, -COR4 (wherein R3 and R4, are independently hydrogen or C1-6alkyl) or -COR5 (wherein R5 is amino, mono or di C1 6alkylamino or an N-linked 4 to 7 membered heterocyclic group); p is 0, 1 or 2 or 3; Q is a 6- membered aromatic group or a 6-membered heteroaromatic group; A is -(CH2-CH2)-, -(CH=CH)-, or a group -(CHR7)- wherein R7 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy or C1 6alkylthio; R2 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C1-6alkanoyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1 6alkylthio, amino, mono or di C1 6alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is oxygen, sulfur, -CH2- or NR8 wherein R8 is hydrogen or C1-6alkyl; Y is a single bond, -CH2-, -(CH2)2- or -CH=CH-; and Z is an optionally substituted N-linked heterocyclic group or a C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, or Z is -NR9R10 where R9 and R10 are independently hydrogen or C1-6alkyl. Methods of preparation and uses thereof in therapy, such as for depression or anxiety, are also disclosed.

  公开了具有式（I）的化合物及其药学上可接受的盐：其中R1是卤素、氰基、C1-6烷基、C3-7环烷基、C3-7环烷氧基、C1-6烷氧基、C1-6烷基硫基、羟基、氨基、单取代或双取代的C1-6烷基氨基、N-连接的4至7成员杂环基、硝基、卤代C1-6烷基、卤代C1-6烷氧基、芳基、-COOR3、-COR4（其中R3和R4独立地是氢或C1-6烷基）或-COR5（其中R5是氨基、单取代或双取代的C1-6烷基氨基或N-连接的4至7成员杂环基）；p为0、1、2或3；Q为6-成员芳基或6-成员杂芳基；A为-(CH2-CH2)-、-(CH=CH)-或一个基团-(CHR7)-其中R7是氢、卤素、羟基、氰基、硝基、C1-6烷基、C3-7环烷基、C3-7环烷氧基、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基或C1-6烷基硫基；R2是氢、卤素、羟基、氰基、硝基、C1-6烷基、C1-6烷酰基、C3-7环烷基、C3-7环烷氧基、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、C1-6烷基硫基、氨基、单取代或双取代的C1-6烷基氨基或N-连接的4至7成员杂环基；X是氧、硫、-CH2-或NR8其中R8是氢或C1-6烷基；Y是单键、-CH2-、-(CH2)2-或-CH=CH-；Z是一个可选择取代的N-连接杂环基或含有至少一个氮的C-连接的4至7成员杂环基，或Z是-NR9R10其中R9和R10独立地是氢或C1-6烷基。还公开了其制备方法和在治疗中的用途，例如用于抑郁症或焦虑症。
• [EN] COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY<br/>[FR] COMPOSES PRESENTANT UNE AFFINITE AVEC LE RECEPTEUR 5HT2C ET UTILISATION THERAPEUTIQUE DE CEUX-CI
  申请人：GLAXO GROUP LTD

  公开号：WO2003089409A1

  公开（公告）日：2003-10-30

  Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: wherein R1 is hydrogen, hydroxy, fluoro, chloro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy or haloC1-6alkoxy; m is 0 when ======= is a double bond and m is 1 when ======= is a single bond; R2 is hydrogen, halogen, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylthio, amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is -(CH2-CH2)-, -(CH=CH)-, -(CH2)3-, -C(CH3)2-, -(CH=CH-CH2)-, -(CH2-CH=CH)- or a group -(CHR5)- wherein R5 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy or C1-6alkylthio; R3 is halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy, C1-6alkylthio, hydroxy, amino, mono- or di-C1-6alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC1-6alkyl, haloC1-6alkoxy, aryl, arylC1-6alkyl, arylC1-6alkyloxy, arylC1-6alkylthio or COOR6, CONR7R8 or COR9 wherein R6, R7, R8 and R9 are independently hydrogen or C1-6alkyl; p is 0, 1 or 2 or 3; R4 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C1-6alkanoyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylthio, amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group; Y is oxygen, sulfur, -CH2- or NR10 wherein R10 is hydrogen or C1-6alkyl; D is a single bond, -CH2-, -(CH2)2- or -CH=CH-; and Z is an optionally substituted C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, an optionally substituted N-linked 4 to 7 membered heterocyclic group, or Z is -NR11R12 where R11 and R12 are independently hydrogen or C1-6alkyl. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression and anxiety, are also disclosed.

  公式（I）的化合物或其药学上可接受的盐被披露：其中R1是氢，羟基，氟，氯，C1-6烷基，C3-7环烷基，C3-7环烷氧基，C1-6烷氧基或卤代C1-6烷氧基；当=======是双键时，m为0，当=======是单键时，m为1；R2是氢，卤素，氰基，硝基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基，C1-6烷硫基，氨基，单或双C1-6烷基氨基或N-连接的4至7成员杂环基；X是-(CH2-CH2)-，-(CH=CH)-，-(CH2)3-，-C(CH3)2-，-(CH=CH-CH2)-，-(CH2-CH=CH)-或一个基团-(CHR5)-其中R5是氢，卤素，羟基，氰基，硝基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基或C1-6烷硫基；R3是卤素，氰基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，C1-6烷氧基，C1-6烷硫基，羟基，氨基，单或双C1-6烷基氨基，N-连接的4至7成员杂环基，硝基，卤代C1-6烷基，卤代C1-6烷氧基，芳基，芳基C1-6烷基，芳基C1-6烷氧基，芳基C1-6烷硫基或COOR6，CONR7R8或COR9其中R6，R7，R8和R9独立地是氢或C1-6烷基；p是0，1，2或3；R4是氢，卤素，羟基，氰基，硝基，C1-6烷基，C1-6烷酰基，C3-7环烷基，C3-7环烷氧基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基，C1-6烷硫基，氨基，单或双C1-6烷基氨基或N-连接的4至7成员杂环基；Y是氧，硫，-CH2-或NR10其中R10是氢或C1-6烷基；D是单键，-CH2-，-(CH2)2-或-CH=CH-；Z是含有至少一个氮的可选择取代的C-连接的4至7成员杂环基，可选择取代的N-连接的4至7成员杂环基，或Z是-NR11R12其中R11和R12独立地是氢或C1-6烷基。还披露了其制备方法和在治疗中的用途，特别是用于中枢神经系统疾病如抑郁症和焦虑症。
• [EN] AZEPINO [4, 5-B] INDOLES AND METHODS OF USE<br/>[FR] AZÉPINO[4,5-B]INDOLES ET PROCÉDÉS POUR LEUR UTILISATION
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2010051503A1

  公开（公告）日：2010-05-06

  This disclosure relates to new azepino[4,5-b]indole compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new 1, 2,3,4,5, 6-tetrahydroazepino[4,5-b]indoles. Pharmaceutical compositions are also provided.

  这份披露涉及新的azepino[4,5-b]indole化合物，可用于调节个体中的组胺受体。描述了新的化合物，包括新的1, 2, 3, 4, 5, 6-六氢azepino[4,5-b]indoles。还提供了药物组合物。
• [EN] IMIDAZOPYRIMIDINONES AND USES THEREOF<br/>[FR] IMIDAZOPYRIMIDINONES ET LEURS UTILISATIONS
  申请人：AVEXA LTD

  公开号：WO2010000031A1

  公开（公告）日：2010-01-07

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. The present invention further provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. Pharmaceutical compositions comprising a compound of formula (I) are also provided.

  本发明提供了一种式（I）的化合物或其药用可接受的衍生物、盐或前药。本发明还提供了一种治疗或预防受试者病毒感染的方法，包括向该受试者施用一定剂量的式（I）的化合物或其药用可接受的衍生物、盐或前药。还提供了含有式（I）的化合物的药物组合物。